As of 2025-09-17, the EV/EBITDA ratio of Revance Therapeutics Inc (RVNC) is -4.67. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RVNC's latest enterprise value is 764.47 mil USD. RVNC's TTM EBITDA according to its financial statements is -163.87 mil USD. Dividing these 2 quantities gives us the above RVNC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 6.8x - 10.8x | 7.6x |
| Forward P/E multiples | 8.8x - 16.0x | 12.4x |
| Fair Price | (17.46) - (20.66) | (19.29) |
| Upside | -578.2% - -666.0% | -628.6% |
| Date | EV/EBITDA |